3985 Research Park Drive	
(Commission File Number)	(IRS Employer Identification No.)
01-12584	13-3808303
(State or other jurisdiction of incorporation)	
Delaware	
(Exact name of registrant as specified in charter)	
-	
Pipex Pharmaceuticals, Inc.	
Date of Report (date of earliest event reported): April 2, 2007	
Pursuant to Section 13 or 15(d) of the Securities Exchange Act	of 1934
CURRENT REPORT	
FORM 8-K	
WASHINGTON, D.C. 20549	
SECURITIES AND EXCHANGE COMMISSION	
UNITED STATES	
Form 8-K April 02, 2007	
PIPEX PHARMACEUTICALS, INC.	

Ann Arbor, MI 48108
(Address of principal executive

(Address of principal executive offices and zip code)

(734) 332-7800

(Registrant s telephone number including area code)

N/A (Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- O Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- O Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- O Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On April 2, 2007, Pipex Pharmaceuticals, Inc., a Delaware corporation (the Registrant"), issued the attached press release that included financial information for its fourth quarter and fiscal year ended December 31, 2006. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant s registration statements or other filings with the Commission.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated April 2, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 2, 2007

Pipex Pharmaceuticals, Inc.

(Registrant)

By: /s/ Steve H. Kanzer

Name: Steve H. Kanzer

Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Exhibits.

99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated April 2, 2007